// App-Quantinova.ai

POS0195 (2021) : GUSELKUMAB TREATMENT MODULATES CORE PSORIATIC ARTHRITIS GENE EXPRESSION IN TWO PHASE 3 CLINICAL TRIALS (DISCOVER-1 AND -2)

Researchers

Presenter

  • S. Siebert

Principal Investigators

  • K. Sweet

  • C. T. Ritchlin

  • E. C. Hsia

  • A. Kollmeier

  • X. L. Xu

  • Q. Song

  • M. Miron

Medical Centers

  • University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom

  • Janssen Research & Development, Raritan, United States of America

  • University of Rochester, Allergy/Immunology and Rheumatology, Rochester, United States of America

  • University of Pennsylvania School of Medicine, Immunology, Philadelphia, United States of America

  • Janssen Research & Development, LLC, Immunology, San Diego, CA, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved